Biotech Values

[ghmm]

Maybe someone with a better understanding of the Orphan Drug Law could explain this to me then. If Tercica had their product approved first shouldn't the only way Insmed's been approved was to offer an advantage over Tercica's? Unless for Orphan drug going from 2x to 1x dosing is considered enough? I thought they (Insmed) claimed other advantages too (whether real or not I can't say).